日本新薬【JP:4516】損益計算書
時価総額
¥3986.8億
PER
14.5倍
医薬品事業ではシオエ製薬㈱やNS Pharma, Inc.と連携し、機能食品事業ではタジマ食品工業㈱が受託製造を行う。
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| 売上高 | 67,304 | 69,941 | 76,517 | 79,991 | 84,209 | 98,781 | 101,448 | 114,716 | 116,637 | 121,885 | 137,547 | 144,175 | 148,255 | 160,232 |
| 売上原価 | - | - | - | 41,226 | 44,016 | 44,835 | 46,929 | 50,952 | 53,155 | 49,954 | 50,191 | 55,980 | 50,234 | 51,116 |
| 売上総利益 | - | - | - | 38,764 | 40,192 | 53,946 | 54,519 | 63,764 | 63,481 | 71,931 | 87,293 | 88,195 | 98,021 | 109,115 |
| 売上総利益率（％） | - | - | - | |||||||||||
| 営業利益 | - | - | - | 8,562 | 8,549 | 15,280 | 17,079 | 20,644 | 21,668 | 26,134 | 32,948 | 30,049 | 33,295 | 35,450 |
| 営業費用 | - | - | - | 30,202 | 31,643 | 38,666 | 37,439 | 43,119 | 41,813 | 45,796 | 32,173 | 34,812 | 34,959 | 38,011 |
| 経常（税引前）利益 | 6,193 | 7,209 | 8,598 | 8,928 | 8,952 | 16,244 | 17,451 | 21,540 | 22,442 | 26,760 | 33,301 | 30,489 | 33,616 | 36,135 |
| 法人税等合計 | - | - | - | 3,039 | 2,605 | 3,712 | 4,482 | 5,217 | 5,553 | 8,038 | 8,303 | 7,669 | 7,762 | 3,574 |
| 純利益 | 3,543 | 4,428 | 5,491 | 5,889 | 6,346 | 11,765 | 12,969 | 16,323 | 16,888 | 20,721 | 24,986 | 22,812 | 25,851 | 32,558 |
| 一株あたり利益 | 55.04 | 68.87 | 85.25 | 87.26 | 94.1 | 174.42 | 192.31 | 242.04 | 250.42 | 307.37 | 370.97 | 338.7 | 383.82 | 483.4 |
| 希薄化後一株あたり利益 | - | - | - | - | - | - | - | - | - | - | - | - | - | 483.26 |
| 配当性向（%） | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 一株あたり配当金 | 19 | 21 | 23 | 25 | 28 | 48 | 52 | 70 | 86 | 99 | 110 | 114 | 124 | 124 |